NU553 Asthma Lecture Notes

Student Name

Purdue University Globle 

NU553 Advanced Pharmacology and Pharmacotherapeutics

Prof. Name

Date

Asthma, COPD, Pneumonia, Tuberculosis, and Tobacco Cessation: Evidence-Based Pharmacologic Management

Effective management of asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis (TB), and tobacco dependence requires accurate diagnosis, guideline-directed treatment, and patient education. Asthma treatment focuses on controlling airway inflammation and preventing exacerbations, while COPD management aims to reduce symptoms, improve quality of life, and slow disease progression. Pneumonia therapy depends on the patient’s age, severity, and likely pathogen, whereas TB requires prolonged multidrug therapy to prevent resistance. Smoking cessation remains one of the most effective interventions for improving respiratory health and reducing disease progression.

Understanding Asthma

Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow obstruction and airway hyperresponsiveness. Patients typically experience recurring episodes of wheezing, coughing, chest tightness, and shortness of breath.

Asthma severity is generally classified into:

• Mild intermittent

• Mild persistent

• Moderate persistent

• Severe persistent

The primary goal of asthma treatment is to achieve long-term symptom control while minimizing the risk of severe exacerbations.

Short-Acting Beta-Agonists (SABAs): Quick-Relief Rescue Therapy

Short-acting beta-agonists (SABAs) provide rapid bronchodilation by relaxing airway smooth muscle. They are commonly known as rescue inhalers because they quickly relieve acute asthma symptoms.

Common Uses

• Acute asthma attacks

• Exercise-induced bronchospasm

• Temporary relief of wheezing and shortness of breath

Common Medications

• Albuterol (Ventolin®, ProAir®)

• Levalbuterol (Xopenex®)

Although SABAs remain effective rescue medications, current Global Initiative for Asthma (GINA) guidelines advise against using SABA alone as long-term therapy because it does not address airway inflammation and may increase the risk of severe exacerbations.

Long-Acting Beta-Agonists (LABAs): Long-Term Symptom Control

Long-acting beta-agonists maintain bronchodilation for approximately 12 hours or longer, helping prevent asthma symptoms throughout the day.

Important Points

• Used for maintenance therapy only

• Never prescribed alone in asthma

• Must always be combined with an inhaled corticosteroid (ICS)

Common Examples

• Salmeterol (combined with fluticasone in Advair®)

• Formoterol (combined with budesonide in Symbicort®)

Combination therapy improves asthma control while reducing the risk associated with LABA monotherapy.

Inhaled Corticosteroids (ICS): The Foundation of Asthma Treatment

Inhaled corticosteroids are considered the cornerstone of persistent asthma management because they directly reduce airway inflammation.

Regular daily use significantly decreases:

• Asthma exacerbations

• Hospitalizations

• Airway inflammation

• Need for rescue inhalers

Common ICS Medications

• Fluticasone (Flovent®)

• Budesonide (Pulmicort®)

• Beclomethasone (Qvar®)

Patients should rinse their mouth after each use to reduce the risk of oral candidiasis.

Long-Acting Muscarinic Antagonists (LAMAs)

Long-acting muscarinic antagonists block muscarinic receptors in the airways, producing sustained bronchodilation.

Although traditionally used for COPD, LAMAs are increasingly recommended for patients with uncontrolled asthma despite receiving ICS/LABA therapy.

Common LAMA Medications

• Tiotropium (Spiriva®)

• Umeclidinium (Incruse Ellipta®)

• Glycopyrrolate (Seebri Neohaler®, Lonhala Magnair®)

LAMAs reduce bronchoconstriction and improve lung function but are not intended for immediate symptom relief.

Current Asthma Treatment Guidelines

Modern asthma management follows a stepwise treatment approach based on disease severity and symptom control.

Two major guidelines are commonly referenced:

GINA Guidelines

• Six-step treatment approach

• Discourages SABA-only therapy

• Recommends ICS-containing therapy even for mild asthma

• Track 1 recommends as-needed low-dose ICS-formoterol for many patients

National Asthma Education and Prevention Program (EPR)

• Five-step treatment model

• Previously allowed PRN SABA alone for Step 1 asthma

• Continues emphasizing inhaled corticosteroids for persistent disease

Both guidelines recommend regularly reassessing asthma control and stepping therapy up or down as appropriate.

Stepwise Asthma Therapy

Before initiating treatment, clinicians should determine asthma severity and symptom frequency.

Common medication classes include:

• Short-acting beta-agonists (SABAs)

• Long-acting beta-agonists (LABAs)

• Inhaled corticosteroids (ICS)

• Long-acting muscarinic antagonists (LAMAs)

• Leukotriene receptor modifiers

Patients should also receive:

• A personalized asthma action plan

• Peak flow meter education when appropriate

• Instruction on proper inhaler technique

Understanding Chronic Obstructive Pulmonary Disease (COPD)

COPD is a progressive respiratory disorder characterized by persistent airflow limitation that is not fully reversible.

Diagnosis is confirmed using spirometry.

A post-bronchodilator FEV1/FVC ratio below 70% supports the diagnosis.

Disease severity is commonly classified by FEV1:

Clinical Types of COPD

Emphysema

Typical characteristics include:

• Barrel-shaped chest

• Pursed-lip breathing

• Thin body habitus

• Historically described as “pink puffers”

Chronic Bronchitis

Typical findings include:

• Chronic productive cough

• Cyanosis

• Peripheral edema

• Historically described as “blue bloaters”

Goals of COPD Management

Treatment focuses on:

• Slowing disease progression

• Improving quality of life

• Reducing exacerbations

• Improving exercise tolerance

• Preventing hospitalizations

Smoking cessation remains the single most important intervention.

COPD Medications

Long-Acting Beta-Agonists (LABAs)

Examples include:

• Salmeterol

• Formoterol

LABAs improve symptoms and reduce exacerbation frequency.

Long-Acting Muscarinic Antagonists (LAMAs)

Common medications include:

• Tiotropium (Spiriva®)

• Ipratropium (Atrovent®)

These agents reduce airflow obstruction but have a slower onset than rescue inhalers.

Combination Bronchodilator Therapy

Patients with significant airflow limitation often benefit from combining bronchodilators, such as:

• Albuterol + Ipratropium (Combivent®)

• Formoterol + Tiotropium

Combination therapy generally provides greater improvement in lung function than either medication alone.

Methylxanthines

Theophylline may be considered in selected patients with severe COPD.

However, its use is limited because:

• Therapeutic and toxic levels are close together

• Frequent monitoring is required

• Numerous drug interactions occur

COPD Exacerbation Treatment

During acute exacerbations:

• Prednisone 40 mg daily for approximately 5–10 days is commonly recommended.

• Systemic corticosteroids shorten recovery time.

• They improve lung function.

• They decrease hypoxemia.

Long-term oral corticosteroid therapy is generally not recommended because of significant adverse effects.

Oxygen Therapy in COPD

Supplemental oxygen is indicated for:

• Acute COPD exacerbations with hypoxemia

• Chronic resting oxygen saturation below approximately 88%

Long-term oxygen therapy has been shown to improve survival in patients with severe chronic hypoxemia.

Pneumonia Overview

Pneumonia is an infection of the lung parenchyma caused by bacteria, viruses, fungi, or atypical organisms.

Common clinical findings include:

• Fever

• Cough

• Leukocytosis

• Abnormal chest imaging

Chest radiographs may require four weeks or longer to completely normalize after clinical recovery.

Community-Acquired Pneumonia in Adults

Patients with comorbidities or risk factors for drug-resistant Streptococcus pneumoniae may receive:

• Respiratory fluoroquinolones (levofloxacin, moxifloxacin, gemifloxacin)

• Beta-lactam plus macrolide combination therapy

• Doxycycline as an alternative when appropriate

Treatment selection should consider local antimicrobial resistance patterns and individual patient factors.

Pediatric Pneumonia Management

The most common bacterial cause of pediatric pneumonia is Streptococcus pneumoniae.

Likely pathogens vary with age.

Infants (4–16 weeks)

Consider:

• Chlamydia trachomatis

Treatment options include:

• Azithromycin

• Erythromycin

Children Younger Than Five Years

Most common cause:

• Streptococcus pneumoniae

Treatment may include:

• High-dose amoxicillin

• Ceftriaxone for severe illness

• Clindamycin or macrolides in selected penicillin-allergic patients

Children Older Than Five Years

Atypical organisms become more common, particularly:

• Mycoplasma pneumoniae

Treatment options include:

• Azithromycin

• Clarithromycin

• Erythromycin

Tobacco Cessation Therapies

Smoking cessation significantly reduces the risk of COPD progression, cardiovascular disease, and many cancers.

Evidence-based treatments include:

• Nicotine gum

• Nicotine lozenges

• Nicotine patches

• Nicotine nasal spray

• Bupropion

• Varenicline

• Behavioral counseling

Combining medication with counseling consistently produces the highest quit rates.

Tuberculosis (TB)

Tuberculosis is caused by Mycobacterium tuberculosis and spreads primarily through inhalation of airborne respiratory droplets.

Treatment requires multiple medications to prevent drug resistance.

Common first-line medications include:

• Isoniazid (INH)

• Rifampin

• Ethambutol

• Pyrazinamide (during the initial treatment phase)

Treatment duration commonly ranges from six to nine months depending on the clinical scenario and drug susceptibility.

Monitoring During Tuberculosis Treatment

Routine monitoring should include:

• Monthly sputum cultures until negative

• Baseline and follow-up liver function testing

• Bilirubin

• Serum creatinine

• Complete blood count

• Platelet count

Patients receiving isoniazid should also be monitored for:

• Hepatitis

• Peripheral neuropathy

Vitamin B6 (pyridoxine) supplementation is often recommended to reduce neuropathy risk in susceptible individuals.

Latent Tuberculosis Infection

Latent TB infection occurs when a patient has evidence of TB infection without symptoms or radiographic evidence of active disease.

Management includes:

• Appropriate antimicrobial therapy

• Monthly clinical monitoring

• Patient education to improve medication adherence

• Monitoring for adverse drug reactions

Early treatment of latent TB substantially reduces the risk of progression to active disease.

Key Clinical Points

• Inhaled corticosteroids remain the foundation of persistent asthma treatment.

• LABAs should never be used alone in asthma and should always be combined with an ICS.

• LAMAs are first-line maintenance medications for many patients with COPD and may benefit selected patients with uncontrolled asthma.

• Spirometry confirms COPD diagnosis, with an FEV1/FVC ratio below 70% supporting airflow obstruction.

• Smoking cessation is the most effective intervention for slowing COPD progression.

• Community-acquired pneumonia treatment varies based on patient age, comorbidities, and likely pathogens.

• Tuberculosis requires prolonged multidrug therapy with careful laboratory monitoring.

• Patient education, medication adherence, and regular follow-up improve long-term respiratory outcomes.

Frequently Asked Questions

What is the difference between a SABA and a LABA?

A SABA provides rapid relief during an asthma attack and is used as a rescue inhaler. A LABA provides long-lasting bronchodilation for maintenance therapy and must always be combined with an inhaled corticosteroid in patients with asthma.

Why are inhaled corticosteroids considered essential in asthma?

Inhaled corticosteroids reduce chronic airway inflammation, decrease asthma exacerbations, improve lung function, and lower hospitalization rates, making them the preferred long-term controller medication.

When are LAMAs used in asthma?

LAMAs may be added for patients with moderate-to-severe asthma who continue experiencing symptoms despite optimized ICS/LABA therapy.

How is COPD diagnosed?

COPD is diagnosed primarily through spirometry. A post-bronchodilator FEV1/FVC ratio below 70% confirms persistent airflow obstruction.

Why is smoking cessation important for COPD?

Stopping smoking slows disease progression, decreases exacerbations, improves lung function decline, and increases overall survival.

What medications are commonly used to treat tuberculosis?

First-line therapy typically includes isoniazid, rifampin, pyrazinamide, and ethambutol during the intensive treatment phase, followed by continuation therapy based on clinical guidelines and susceptibility testing.

Asthma treatment should prioritize inhaled corticosteroid-containing therapy because it reduces airway inflammation and prevents severe exacerbations. COPD management relies on bronchodilators, smoking cessation, pulmonary rehabilitation, and oxygen therapy when indicated. Pneumonia treatment depends on patient age, comorbidities, and likely pathogens, while tuberculosis requires prolonged multidrug therapy with regular monitoring. Following evidence-based guidelines and promoting medication adherence significantly improve long-term respiratory health outcomes.

NU553 Asthma Lecture Notes

Patients with persistent asthma should receive inhaled corticosteroids as the primary controller medication, while rescue inhalers are reserved for rapid symptom relief. Current international guidelines discourage SABA-only therapy due to the increased risk of severe asthma exacerbations.

Spirometry remains the gold standard for diagnosing COPD. A post-bronchodilator FEV1/FVC ratio below 70% confirms persistent airflow obstruction, and smoking cessation remains the single most effective intervention for slowing disease progression.

Tuberculosis management requires multidrug therapy, routine laboratory monitoring, monthly sputum evaluation when indicated, and patient education to ensure treatment completion and reduce antimicrobial resistance.

References

Global Initiative for Asthma. (2025). Global strategy for asthma management and prevention. https://ginasthma.org

Global Initiative for Chronic Obstructive Lung Disease. (2025). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org

Metlay, J. P., Waterer, G. W., Long, A. C., et al. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67. https://doi.org/10.1164/rccm.201908-1581ST

Centers for Disease Control and Prevention. (2025). Tuberculosis (TB): Clinical care and treatment. https://www.cdc.gov/tb

Centers for Disease Control and Prevention. (2024). Smoking and tobacco use: Quitting smoking. https://www.cdc.gov/tobacco

National Heart, Lung, and Blood Institute. (2020). 2020 focused updates to the asthma management guidelines. https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines